Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 18 to 79

Understanding how glucose and fat affect blood vessel health

Official title: Reversing Glucose and Lipid-mediated Vascular Dysfunction (REGAL)

Run by University of Kansas Medical Center · NCT04832009 · Data updated 2026-11-12

This study is testing how sugar and fat in the body affect blood vessel health and blood pressure in healthy adults.

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years to 79 Years
SexAll
Enrollment46 (estimated)
SponsorUniversity of Kansas Medical Center
Academic / other
Locations1 site (Kansas City, Kansas)
StatusRecruiting
StartedMay 9, 2022
Main results expectedAugust 1, 2026
Study endsAugust 1, 2027
Registry record updatedJune 5, 2025
Trial IDNCT04832009 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are lean adults aged 18-79 with normal insulin sensitivity and stable blood pressure below 140/90 mmHg.

Probably not a fit

Patients with diabetes, hypertension, or a history of cardiovascular or vascular diseases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to investigate the impact of glucose and lipids on vascular function in lean, healthy adults and their potential role in developing high blood pressure. It will utilize the microneurographic technique to measure muscle sympathetic nerve activity, which is crucial for blood pressure regulation. Participants will receive interventions including dextrose, intralipid, saline, and ascorbic acid to assess the restoration of nerve and blood vessel function affected by high glucose and lipid levels.

Why it matters

Potential benefit: If successful, this study could lead to new strategies for preventing or treating hypertension by improving vascular health.

How similar studies have gone: While the approach of using antioxidants to improve vascular function is known, this specific investigation into glucose and lipid effects in lean adults is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Lean: BMI \< 25 kg/m
* Normal insulin sensitivity: (calculation based on fasting glucose and insulin concentrations in blood)
* Middle-aged: 18-79 years
* Blood pressure: \< 140 (systolic) and \< 90 mmHg (diastolic
* Weight stable (+/- 5 lbs) for the previous 3 months
* Participants must be willing and able to discontinue taking any vitamin C or E supplements or omega-3 fatty acids beginning 2 weeks prior.
* Able and willing to provide written informed consent

Exclusion Criteria:

* Diabetes mellitus Type I or Type II: fasting glucose \< 126 mg/dL and/or HbA1c \< 6.5%
* Current smoker or History of smoking in the past 3 months.
* Hyperlipidemia: Fasting triglycerides \< 250 mg/dL
* Hypertension: \>130/80 mmHg
* History of heart disease (e.g., myocardial infarction, stent, heart attack, stroke, heart failure, valvular heart disease, cardiomyopathy)
* History of vascular disease (e.g., bypass, stroke)

Where it's running

  • University of Kansas Medical Center
    Kansas City, Kansas, United States
    Recruiting

Study contacts

  • Principal investigator: Seth W. W Holwerda, PhD — University of Kansas Medical Center
  • Study coordinator: Seth W Holwerda, PhD
  • Email: sholwerda@kumc.edu
  • Phone: 9729223230

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.